- Ticker
- ABEO
- Price
- 2.76
- Stock movement down
- -0.06 (-2.13%)
- Company name
- Abeona Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 47.41M
- Ent verdi
- 65.02M
- Pris/omsetning
- 10.91
- Pris/bok
- 3.08
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- 961.54%
- 3 års avkastning
- 4.48%
- 5 års avkastning
- -29.32%
- 10 års avkastning
- -16.62%
Sist oppdatert: 2023-02-03
UTBYTTE
ABEO betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 10.91 |
| Pris til bok | 3.08 |
| EV i forhold til salg | 14.96 |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 17.18M |
| EPS (TTM) | -13.28 |
| FCF per aksje (TTM) | -7.64 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 4.35M |
| Bruttofortjeneste (TTM) | 4.00M |
| Driftsinntekter (TTM) | -84.63M |
| Netto inntekt (TTM) | -85.25M |
| EPS (TTM) | -13.28 |
| EPS (1 år fremover) | -1.79 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 91.95% |
| Driftsmargin (TTM) | -1947.33% |
| Fortjenestemargin (TTM) | -1961.64% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 5.73M |
| Netto fordringer | 1.05M |
| Samlede omløpsmidler | 25.50M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 0.00 |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 38.76M |
| Leverandørgjeld | 1.75M |
| Kortsiktig/nåværende langsiktig gjeld | 8.29M |
| Sum kortsiktig gjeld | 12.60M |
| Sum gjeld | 23.35M |
| Aksjonærenes egenkapital | 15.41M |
| Netto varige driftsmidler | 15.41M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -46.16M |
| Kapitalutgifter (TTM) | 2.91M |
| Fri kontantstrøm (TTM) | -49.07M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -553.12% |
| Avkastning på eiendeler | -219.95% |
| Avkastning på investert kapital | -495.00% |
| Kontantavkastning på investert kapital | -284.93% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 2.77 |
| Daglig høy | 2.90 |
| Daglig lav | 2.73 |
| Daglig volum | 158K |
| Tidenes høyeste | 47188.00 |
| 1 år analytikerestimat | 21.33 |
| Beta | 1.25 |
| EPS (TTM) | -13.28 |
| Utbytte per aksje | - |
| Ex-div dato | 22 Jul 2022 |
| Neste dato for resultatpresentasjon | 29 Mar 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ABEO | S&P500 | |
| Nåværende prisfall fra toppnotering | -99.99% | -13.68% |
| Høyeste prisfall | -100.00% | -56.47% |
| Dato for høyeste fall | 17 Jun 2022 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -92.03% | -11.49% |
| Gj.snittlig tid til ny topp | 404 days | 13 days |
| Maks tid til ny topp | 7568 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
47.41M
Markedsverdi kategori
Small-cap
Beskrivelse
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Ansatte
90
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Joao Siffert
Land
USA
By
New York
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
14. november 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
8. november 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
3. november 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
3. november 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
3. november 2022
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its inv...
19. oktober 2022
Topline VIITAL™ study results expected within the next monthNEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has ...
4. oktober 2022
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside...
22. september 2022
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel di...
13. september 2022
In this article, we discuss 10 best penny stocks to buy in September. If you want to see more stocks in this selection, check out 5 Best Penny Stocks to Buy in September. As the stock market runs red,...
8. september 2022
Neste side